作者
Andrew F Auld, Katherine L Fielding, Ankur Gupta-Wright, Stephen D Lawn
发表日期
2016/8/1
来源
Transactions of the Royal Society of Tropical Medicine and Hygiene
卷号
110
期号
8
页码范围
432-444
出版商
Oxford University Press
简介
Compared with smear microscopy, the Xpert MTB/RIF assay (Xpert), with superior accuracy and capacity to diagnose rifampicin resistance, has advanced TB diagnostic capability. However, recent trials of Xpert impact have not demonstrated reductions in patient morbidity and mortality. We conducted a narrative review of Xpert impact trials to summarize which patient-relevant outcomes Xpert has improved and explore reasons for no observed morbidity or mortality reductions. We searched PubMed, Google Scholar, Cochrane Library and Embase and identified eight trials meeting inclusion criteria: three individually randomized, three cluster-randomized, and two pre-post trials. In six trials Xpert increased diagnostic yield of bacteriologically-confirmed TB from sputa and in four trials Xpert shortened time to TB treatment. However, all-cause mortality was similar between arms in all six trials reporting this outcome …
学术搜索中的文章
AF Auld, KL Fielding, A Gupta-Wright, SD Lawn - Transactions of the Royal Society of Tropical Medicine …, 2016